Table 1 Characteristics and treatment factors of patients.
Variables | Strata | IG-IMRT | LDR-BT | p-value | |||
|---|---|---|---|---|---|---|---|
n = 269 | n = 488 | ||||||
No. or Median (range) | (%) | No. or Median (range) | (%) | ||||
Age | 71.5 (51–86) | 71 (52–86) | 0.0147 | ||||
T category | 1 | 86 | (32%) | 234 | (48%) | <0.0001 | |
2 | 118 | (44%) | 242 | (49%) | |||
3 | 64 | (24%) | 12 | (2%) | |||
4 | 1 | (0.4%) | 0 | (0%) | |||
iPSA | ng/ml | 9.7 (4–265) | 7.0 (1.4–46) | <0.0001 | |||
Gleason score | −6 | 86 | (32%) | 279 | (57%) | <0.0001 | |
7 | 76 | (28%) | 185 | (38%) | |||
8− | 107 | (40%) | 24 | (5%) | |||
D’Amicos’ risk classification | Low | 47 | (17%) | 193 | (39%) | <0.0001 | |
Intermediate | 72 | (27%) | 222 | (45%) | |||
High | 150 | (56%) | 73 | (15%) | |||
Prescribed dose | 74.8 Gy | 102 | (38%) | LDR-BT 110 Gy plus EBRT 40 Gy | 68 | (14%) | NA |
72.6 Gy | 23 | (9%) | LDR-BT 145 Gy | 420 | (86%) | ||
74 Gy | 119 | (44%) | |||||
72 Gy | 25 | (9%) | |||||
Hormonal therapy | Yes | 176 | (65%) | 156 | (32%) | <0.0001 | |
No | 93 | (35%) | 332 | (68%) | |||
Follow-up | Months | 74.3 (23.2–96) | 60.5 (12–121.6) | <0.0001 | |||
